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ABSTRACT
Background: Indoleamine 2,3-dioxygenase (IDO) is an enzyme that tumors use 
to create a state of immunosuppression. Indoximod is an IDO pathway inhibitor. 
Preclinical studies demonstrated that indoximod combined with chemotherapy was 
synergistic in a mouse model of breast cancer. A phase I 3+3 trial was designed to 
study the combination of docetaxel and indoximod.
Methods: Docetaxel was administered at 60 mg/m2 intravenously every 3 weeks 
dose levels 1-4 and 75 mg/m2 for dose level 5. Indoximod was given at 300, 600, 
1000, 2000, and 1200 mg PO twice daily continuously for levels 1-5, respectively. 
Serum drug levels were measured.
Results: Twenty-seven patients were treated, with 22 evaluable for response. 
DLTs included grade 3 dehydration (level 1), hypotension(level 4), mucositis (level 4) 
and grade 5 enterocolitis (level 2). Dose level 5 is the recommended phase II dose. The 
most frequent adverse events were fatigue (58.6%), anemia (51.7%), hyperglycemia 
(48.3%), infection (44.8%), and nausea (41.4%). There were 4 partial responses 
(2 breast, 1 NSCLC, 1 thymic tumor). No drug-drug interactions were noted.
Conclusions: Docetaxel plus indoximod was well tolerated with no increase in 
expected toxicities or pharmacokinetic interactions. It was active in a pretreated 
population of patients with metastatic solid tumors.
INTRODUCTION
Indoleamine 2,3-dioxgenase (IDO) is a tryptophan-
catabolizing enzyme that inhibits the immune response. 
IDO was first discovered as an enzyme of the placenta, 
essential for the prevention of fetal rejection by maternal 
T cells [1]. It was later determined that IDO played a 
critical role in the modulation of autoimmunity and 
transplantation [2]. Because T cells are sensitive to 
tryptophan deficiency, depletion causes growth arrest in 
the G1 phase of the cell cycle [3, 4]. IDO can deplete the 
local tryptophan supply, thereby blocking the proliferation 
of reactive T lymphocytes [3, 4].
Immune cells are often present at the tumor site, 
not only to recognize and eliminate malignant cells, 
but conversely to aid the tumor in evasion of immune 
destruction [5]. Recent literature has determined that IDO 
can be used by tumor cells to avoid elimination by the host 
immune response [6]. It was hypothesized that an inhibitor 
of IDO would increase the effectiveness of the T-cell 
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response against tumors leading to growth inhibition. 
Indoximod (D-1-methyl-tryptophan) was developed as an 
inhibitor of the IDO pathway. The proposed mechanism 
of action is reversal of the downstream effects of IDO 
activation through amino acid sensing and mTOR 
pathways [7]. Preclinical data support the ability of 
indoximod to reverse IDO-mediated immune suppression 
[8]. The immunosuppressive activity of IDO leads to an 
increase in the number of T-regulatory cells, as measured 
by their Foxp3+/CD4+/CD25+ phenotype. Indoximod 
has also been shown to reduce the number of T-regulatory 
cells [9].
In a study with MMTV-Neu mice, researchers 
looked at the activity of indoximod with and without 
paclitaxel [10]. Mice with palpable tumors were treated 
with control vehicle, indoximod, paclitaxel, or indoximod 
with paclitaxel. A taxane was chosen based on evidence 
that it increased effector T cells at the tumor site [11]. The 
combination produced significantly more tumor regression 
than either agent alone. This synergistic effect was lost 
when the experiment was repeated in immunodeficient 
mice, demonstrating that the benefit was dependent on 
an anti-tumor immune response. Additional preclinical 
data suggested that indoximod can synergize with other 
chemotherapy agents, such as doxorubicin and platinum 
salts [10]. The single-agent phase I trial of indoximod 
demonstrated very good oral bioavailability and a mild 
toxicity profile with no significant myelosuppression, and 
no maximally tolerated dose was identified up to 2000 mg 
orally twice daily [12]. Based on the preclinical data and 
good safety profile of single-agent indoximod, we initiated 
a phase I trial to investigate the combination therapy of 




Eligibility for this study included patients with 
advanced solid tumors, age greater than 18 years, life 
expectancy greater than 4 months, Eastern Cooperative 
Oncology Group (ECOG) performance status 0-2, and 
adequate organ/marrow function. Patients were excluded 
if they met any of the following criteria: 1) chemotherapy/
radiotherapy within the past 3 weeks, 2) untreated 
brain metastases, 3) uncontrolled concurrent major 
illness, 4) current use or previous allergic reaction to 
L-tryptophan, 5) active autoimmune disease or chronic 
inflammatory condition requiring use of steroids or 
systemic immunosuppressants, 6) pregnant, 7) AIDS/
HIV infection, or 8) history of gastrointestinal disease 
causing malabsorption/obstruction. In addition, patients 
that received active immunotherapies such as adjuvant 
interferon less than 1 year prior to enrollment were 
excluded. There were no restrictions on number of prior 
lines of therapy, and could have received prior docetaxel in 
the adjuvant (but not metastatic) setting. Any patient who 
received prior experimental immunotherapy consisting 
of targeted monoclonal antibodies was excluded. 
However, patients who received prior therapy with 
approved monoclonal antibodies such as bevacizumab, 
cetuximab, panitumumab, or trastuzumab were eligible. 
Patients were accrued through the Southeast Phase 2 
Consortium consisting of the following locations: H. Lee 
Moffitt Cancer Center and Research Institute, Billings 
Clinic Cancer Center, Massey Cancer Center, Lineberger 
Comprehensive Cancer Center, and the Winship Cancer 
Institute of Emory University. Both men and women and 
members of all races and ethnic groups were eligible for 
this trial.
Study Design
The protocol was approved by the National Cancer 
Institute’s Cancer Therapeutics Evaluation Program and 
conducted in accordance with all federal and institutional 
guidelines. All patients provided written informed consent 
under an Institutional Review Board-approved protocol 
prior to initiation of any study procedure (University of 
South Florida IRB, FWA# FWA00001669).
The study followed a 3+3 escalation design to 
determine the maximum tolerated dose (MTD). The 
MTD is defined as the highest dose level in which less 
than or equal to one out of six patients experiences 
a dose-limiting toxicity (DLT). DLTs were defined 
as 1) non-hematological grade 3 or greater toxicity 
probably attributable to therapy and not to underlying 
disease, 2) absolute neutrophil count of less than 500/
mL for longer than 7 days or neutropenic fever requiring 
hospitalization despite the use of white blood cell colony-
stimulating factors and dose reduction of docetaxel to 
60 mg/m2, 3) grade 4 thrombocytopenia (<25,000/mL), 
and 4) dose delay due to hematological toxicity for more 
than 14 days. Grade 3 hypophysitis and dermatitis were 
the only exceptions to the DLT rule.
This phase I study evaluated the safety of docetaxel 
at 60-75 mg/m2 in combination with escalating doses 
of indoximod (Table 1). Dose level 5 was amended 
after accrual to dose level 4 was completed due to 
pharmacokinetic data from the monotherapy trial that 
revealed maximal absorption was reached at 1200 mg PO 
twice daily.
Indoximod was supplied by the National Cancer 
Institute’s Pharmacy Branch and NewLink Genetics 
Inc (50 mg and 200 mg hard gelatin capsules). It was 
administered orally twice daily for 21-day continuous 
cycles on an empty stomach. Docetaxel was prepared with 
a single-dose diluent containing 13% ethanol in water and 
was then administered intravenously over 1 hour. Standard 
supportive medications, including dexamethasone and 
anti-histamines as required, were used with docetaxel.
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The primary endpoint of this trial was to determine 
the MTD of the indoximod/docetaxel combination using 
Common Terminology Criteria for Adverse Events 4.0. 
Secondary endpoints included the determination of the 
pharmacokinetic data and the overall objective response 
rate per Response Evaluation Criteria in Solid Tumors 
(RECIST) 1.1 criteria.
Safety Evaluations
Complete blood counts and metabolic panels were 
obtained at baseline and every 3 weeks. Pituitary function 
tests (thyroid stimulating hormone, free T4, leutinizing 
hormone, follicular stimulating hormone, and adrenocortical 
hormone) were obtained at baseline and every 6 weeks. 
Patients underwent complete physicals and adverse event 
evaluation once each cycle and as clinically indicated.
Response Evaluation
Overall response rate was determined via the 
criteria described by the RECIST 1.1 guidelines. Baseline 
evaluations were conducted within 14 days prior to the 
start of therapy. Scans were performed within 4 weeks 
prior to the start of therapy. Patients were then reevaluated 
every 6 weeks with diagnostic CT scans. The best overall 
response achieved during study therapy was recorded 
for each patient. The response data presented herein 
underwent independent radiology review. The duration 
of overall response was measured from the time criteria 
were met for complete or partial response until the first 
date that recurrent or progressive disease was documented. 
In patients exhibiting response or disease stabilization, 
treatment was continued until 1) disease progression, 
2) intercurrent illness that prevented further treatment, 
3) unacceptable adverse events despite appropriate 
supportive care, or 4) patient withdrawal from trial.
Pharmacokinetic Methods
Validated liquid chromatography triple quadrupole 
with tandem mass spectrometry (LC/MS/MS) methods 
were used to determine levels of indoximod and 
docetaxel in plasma. The methods were validated per 
ICH/FDA guidelines. Plasma samples were prepared for 
chromatographic injections by protein precipitation (PPT) 
in both instances. However, methods were conducted as 
separate analysis due to the vast differences in analyte 
characteristics.
Indoximod calibration and quality control samples 
were made by adding known amounts of indoximod 
to blank plasma. Indoximod-d3, stable isotope labeled 
internal standard, was used in the assay. A Sirocco 96-
well PPT plate (Waters Corp, Milford, MA) was utilized 
similar to the manufacturer’s suggestion. Samples were 
injected into a ThermoAccela/TSQ Quantum LC/MS/
MS system (Thermo Scientific, San Jose, CA). Mobile 
phase consisted of water and methanol, both containing 
0.1% acetic acid. Gradient pumping conditions were run, 
and samples were maintained at 4°C in the autosampler 
during sequences. Indoximod was separated using a Luna 
C18 (2 x 50 mm, 3 μm) column (Phenomenex, Inc., 
Torrance, CA). Electrospray ionization was employed, 
and multiple reaction monitoring was conducted 
in positive mode utilizing the following molecular 
transitions; 219 →160 and 222 →163 for indoximod 
and indoximod-d3, respectively. Peaks were detected 
and integration was performed with Thermo LC Quan 
software.
The calibration and quality control samples for 
docetaxel were made in similar fashion as previous 
with blank plasma. Docetaxel–d9, stable isotope labeled 
internal standard, was utilized for this analysis. Protein 
precipitation was carried out in an Ostro 96-well PPT plate 
(Waters Corp) according to the manufacturer’s suggestion. 
The same instrument and mobile phase was used as 
previously described. Samples were maintained at 8°C in 
the autosampler during sequences, and gradient pumping 
conditions were used. Docetaxel was separated using a 
Zobrax SB C18 (2.1 x 50 mm, 3.5 μm) column (Agilent 
Technologies, San Jose, CA). Electrospray ionization was 
utilized, and multiple reaction monitoring was conducted 
in negative mode tracking the following molecular 
transitions: 806 →672 and 815 →672 for docetaxel and 





No. of Patients 
Treated






1 60 300 7 28 3 Grade 3 dehydration
2 60 600 6 35 3 Grade 5 colitis
3 60 1000 6 39 3
4 60 2000 2 2 1 Grade 3 hypotension,mucositis
5 75 1200 6 16 2
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docetaxel-d9, respectively. Once again, LC Quan was used 
for detection of peaks and integration.
Calibration curves were generated for each run, 
and patient sample concentrations were back-calculated 
from the corresponding regression line using LC Quan. 
The assays are linear from 5 to 2500 ng/mL for both 
indoximod and docetaxel. Recovery of indoximod from 
plasma is on average greater than 95%. Inter- and intra-
assay variability was less than 9% with a relative mean 
error of less than 10% for indoximod. Docetaxel average 
recovery from plasma was determined to be greater than 
78%. Docetaxel assay inter- and intra-assay variability 
was less than 11% with a relative mean error of less 
than 6%. Plasma concentration-time data for both drugs 
was analyzed by non-compartmental pharmacokinetic 
methods using Phoenix WinNonlin 6.3 (Pharsight Corp., 
Mountain View, CA). Data in the terminal, log-linear 
phase were analyzed by linear regression to estimate 
terminal elimination rate constant and half-life. These 
additional pharmacokinetic parameters were also 




Patient demographics are outlined in Table 2. 
Patients with a variety of cancers were enrolled; however, 
most primary sites were categorized as non-small cell lung 
carcinoma (34%) or breast (28%). Eighty-six percent of 
patients received treatment in the metastatic setting before 
entering the study. Of the four untreated patients, one 
withdrew consent during cycle 1 and was unevaluable for 
response. One of the breast cancer patients was assigned to 
dose level 1 after relapsing within six months of adjuvant 
dose dense doxorubicin/cyclophosphamide/paclitaxel 
chemotherapy. The second breast patient relapsed on 
adjuvant endocrine therapy and was assigned to dose 
level 2. The fourth patient was a stage IIIB unresectable 
lung cancer patient who initially was treated with 
cisplatin/pemetrexed/vorinostat plus radiation, then had 
progression of disease and was assigned to dose level 3. 
Patients received a median of five prior therapies, mostly 
consisting of chemotherapy. Almost all patients were 
ECOG performance status 0 or 1.
Patient Flow
Thirty-three patients were screened for the study 
with five failing to meet all screening criteria. Twenty-
nine patients were then registered for treatment. Two 
patients withdrew consent during cycle 1, with 27 patients 
initiating treatment. One patient began treatment, was 
then found to be ineligible after the first cycle, and was 
replaced. One patient (dose level 2) expired on cycle 1, 
day 10 and was not evaluable for response. Three patients 
withdrew consent during cycle 1 and were not assessed for 
the response endpoint. Twenty-two patients were included 
in the response analysis. Figure 1 shows a chart of patient 
flow through the trial.
Adverse Events
Table 3 lists the frequency of any grade 3, 4, or 
5 toxicities that occurred, as well as any grade 1 or 2 
toxicity with a frequency greater than 25% regardless 
of attribution. Adverse events occurring with the 
highest frequency included grade 1 anemia, fatigue, 
and hyperglycemia (41%, 45%, and 38%, respectively). 
Common grade 3/4 adverse effects included neutropenia 
and febrile neutropenia (both 13%).
Dose-Limiting Toxicities
DLTs included grade 3 dehydration at level 1, 
grade 5 colitis at level 2, and grade 3 hypotension and 
mucositis at level 4. The grade 5 colitis was caused by 
sudden mesenteric ischemia leading to sepsis. The death 
was determined unlikely to be related to indoximod by 
the site investigators, as well as after thorough safety 
review by the protocol monitoring committee. Dose level 
5 (75 mg/m2 of docetaxel + 1200 mg PO twice daily of 
indoximod) was administered to 6 patients without a DLT 
and thus was deemed the maximally tolerated dose level.
Response Rate
The overall objective response rates are summarized 
in Table 4. Four patients achieved a partial response 
(18%), one patient achieved stable disease for longer 
than 6 months (4%), nine patients achieved stable disease 
for less than 6 months (36%), and eight patients had 
progressive disease (36%).
Figure 2 is a waterfall plot of each patient’s best 
overall response. Four breast cancer patients achieved a 
reduction in tumor burden (64.8%, 33%, 14.6%, and 6.2% 
reduction of target lesions). The best of these responders 
was the untreated breast cancer patient in dose level two 
who had received only adjuvant endocrine therapy prior 
to study entry. Two non-small cell lung cancer patients 
showed a reduction in tumor size (56.5% and 8.2%), as 
well as one patient with thymic cancer (78.3% reduction). 
The durations of the objective responses were 15.4 and 5.9 
months in the two breast cancer patients. In the lung cancer 
and thymic cancer patients the duration of response was 
7.1 and 5.9 months respectively. It should be noted that the 
thymic cancer patient discontinued therapy secondary to 
fatigue and not due to confirmed radiographic progression 
of his disease. None of the objective responders were 
previously treated with docetaxel. Five patients showed 
only a slight increase in tumor burden with less than 10% 
growth of target lesions.
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Pharmacokinetics
Indoximod pharmacokinetics were similar to 
results previously reported by our group in the phase I 
single-agent trial [12]. The half-life was 11.3 (±5.0) 
hours (n = 23) and AUC was proportional to dose. When 
comparing day 1 and 8 results, the pharmacokinetics 
for indoximod were consistent, indicating little to 
Table 2.  Patient and Treatment Characteristics (N=29)
Demographic
Sex, n (%)
 Men 15 (51)
 Women 14 (49)
Age
 Mean ± SD 53 +/- 10
 Median (range) 53
Ethnicity, n (%)
 White 25 (86)
 Black 3 (10)
 Other 1 (3)
Disease type, n (%)
 NSCLC 10 (34)
 Breast (4 ER+, 4 TNBC) 8 (28)
 Laryngeal 2 (7)
 Esophageal 2 (7)
 Ovarian 2 (7)
 Uterine 1 (3)
 Thymus 1 (3)
 Liposarcoma 1 (3)
 Rectal 1 (3)
 Pancreas 1 (3)
ECOG Performance Status, n (%)
 0 11 (37)
 1 14 (48)




Previous therapy, n (%)
 Total 25 (86)
 Chemotherapy 24 (83)
 Radiation 9 (31)
 Hormonal/endocrine 5 (17)
 Trastuzumab 2 (7)
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no interaction with docetaxel. When comparing 
AUC(0-inf) on day 1 with AUC(ss) on day 8, results were 
nearly the same. Figure 3 represents AUC comparisons. 
The Cmax of indoximod on day 8 was higher than on day 
1 at two dose levels (600 and 1000 mg), but the standard 
deviation among the patients may have contributed. Dose-
independent pharmacokinetic parameter estimates for 
indoximod can be found in Table 5.
The pharmacokinetics results for docetaxel do not 
appear to be affected by indoximod. The results of the two 
dose levels evaluated were similar to results reported in 
single-agent studies [13]. Dose was proportional to AUC 
and Cmax for the study population. Half-life reported 
here for the entire population, 20.9 (±7.8) hours (n=23), 
was also similar to previous evaluations. Docetaxel 
pharmacokinetics by dose level can be found in Table 6.
DISCUSSION
The field of cancer immunotherapy is undergoing 
a renaissance due to a greater understanding of the 
complex regulatory pathways that cause tumor-related 
immunosuppression. Checkpoint inhibitors such as 
ipilimumab and nivolimumab demonstrated dramatic 
responses and durable long-term disease control in a 
fraction of patients with melanoma and non-small cell 
lung cancer [14-16]. To increase the clinical benefit to 
patients, combination strategies will need to be explored as 
a way to overcome immune suppression mediated by other 
pathways. Indoleamine 2,3 dioxygenase represents one 
such pathway, and there are efforts underway to see how 
IDO inhibition can be used to boost the efficacy of other 
immunotherapies [17]. Another important consideration 
is that the efficacy of some chemotherapeutics and 
targeted monoclonal antibodies is in part dependent on 
their ability to promote an effective anti-tumor response 
[18-21]. Therefore, combining immunomodulators with 
chemotherapy or targeted agents to boost this immune 
response is a logical next step.
This phase I trial provides important information 
on the feasibility and safety of this chemoimmunotherapy 
approach using a taxane and an IDO pathway inhibitor. 
The multiple indications of docetaxel will allow this 
combination to be tested in a variety of solid tumors 
that overexpress IDO, such as breast cancer, non-small 
cell lung cancer, prostate cancer, gastric cancer, and 
oropharyngeal cancer [8]. Indoximod appears to be ideal 
from a safety standpoint in that it does not add significantly 
to the toxicity burden or myelosuppression imposed by 
the chemotherapy agent. Nadir counts were not routinely 
obtained due to the high baseline incidence of neutropenia 
(>90%) from single-agent docetaxel, which would 
make it difficult to ascertain the impact of indoximod 
on asymptomatic neutropenia. This is especially the 
Figure 1: Patient flow diagram
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Table 3.  Adverse events by grade regardless of attribution
Toxicity Grade 1 n(%) Grade 2 n(%) Grade 3 n(%) Grade 4 n(%) Grade 5 n(%)
Hematologic
Anemia 12(41) 8(28) 1(3) 0 0
Leukopenia 0 0 1(3) 2(7) 0
Lymphopenia 0 0 2(7) 0 0
Neutropenia 0 0 1(3) 3(10) 0
Thrombocytopenia 0 0 1(3) 0 0
Endocrine
Hyperglycemia 11(38) 8(28) 1(3) 0 0
Infection
Febrile Neutropenia 0 0 4(14) 0 0
GI Infection 0 0 1(3) 0 0
Gram Negative Infection 0 0 1(3) 0 0
Pneumonia 0 0 2(7) 0 0
Sepsis 0 0 0 1(3) 0
Skin Infection 0 0 1(3) 0 0
Tooth Abscess 0 0 1(3) 0 0
Gastrointestinal
Abdominal Pain 0 0 1(3) 0 0
Anorexia 8(28) 0 0 0 0
Bowel Perforation 0 0 0 1(3) 0
Colitis 0 0 0 0 1(3)*
Constipation 8(28) 0 0 0 0
Dehydration 0 0 2(7)* 0 0
Diarrhea 8(28) 0 0 0 0
Nausea 10(34) 0 1(3) 0 0
Oral Mucositis 0 0 1(3)* 0 0
Vomiting 8(28) 0 0 0 0
Metabolic
Hypercalcemia 0 0 1(3) 0 0
Hypoalbuminemia 9(31) 0 2(7) 0 0
Hypocalcemia 0 0 1(3) 1(3) 0
Hypokalemia 0 0 1(3) 0 0
Hyponatremia 0 0 4(14) 0 0
Pulmonary
Cough 6(21) 0 0 0 0
Dyspnea 8(28) 0 1(3) 0 0
Pleuritic Chest Pain 0 0 1(3) 0 0
(Continued)
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case in a smaller phase I, pretreated patient population 
with diminished bone marrow reserves. Therefore, our 
safety evaluations focused on clinically relevant febrile 
neutropenic events or prolonged myelosuppression that 
would delay subsequent therapy. The febrile neutropenia 
rate of 14% was not significantly greater than what 
has been described in phase III trials, but it should be 
noted that these historical rates were shown in first-line 
metastatic patients [22].
The challenge of fully assessing increased toxicity 
from an investigational compound added to an agent 
such as docetaxel within a small phase I trial is difficult. 
However, our ongoing randomized phase II combination 
trial in first-line metastatic breast cancer patients 
incorporates interim safety analyses with early stopping 
rules for excessive toxicity. This will allow a more 
adequately powered and meaningful assessment regarding 
whether the combination of docetaxel and indoximod is 
more toxic than docetaxel monotherapy. As far as the 
activity of the combination is concerned, any definitive 
comparative interpretation between the combination and 
historical activity of docetaxel monotherapy is not possible 
in this small, heterogeneous group of patients. The fact 
that 4 of the 8 breast cancer patients showed some degree 
Toxicity Grade 1 n(%) Grade 2 n(%) Grade 3 n(%) Grade 4 n(%) Grade 5 n(%)
Renal
Increased Creatinine 0 0 1(3) 0 0
 Hematuria 0 0 1(3) 0 0
Vascular
Hypotension 0 0 3(10)* 0 0
Muskuloskeletal
Alopecia 8(28) 0 0 0 0
Arthralgia 0 0 1(3) 0 0
Bone Pain 0 0 1(3) 0 0
Neurologic
Peripheral Neuropathy 7(24) 0 1(3) 0 0
Weakness 0 0 1(3) 0 0
Constitutional Symptoms
Fatigue 13(45) 13(45) 0 0 0
Pain
Headache 0 0 2(7) 0 0
Jaw Pain 0 0 1(3) 0 0
General Disorders
Multi-Organ Failure 0 0 0 1(3) 1(3)
Table 4.  Overall response rate in 22 patients included in efficacy analysis
Objective Response Rate Number of Patients, n (%)
Complete response 0
Partial response 4 (18)
Stable disease > 6 months 1 (4)
Stable disease < 6 months 9 (40)
Progressive disease 8 (36)
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Figure 2: A waterfall plot demonstrating the greatest extent of target lesion measurement changes expressed as a percentage 
of the baseline measurement.
Figure 3: Mean area under the curve (AUC) values of indoximod on cycle 1 days 1 (blue bars) and 8 (green bars) 
across the five dose levels of indoximod on the x axis. Docetaxel did not significantly affect indoximod AUC values at steady state 
(ss) across all dose levels.
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of anti-tumor activity is an encouraging preliminary signal 
and warrants further investigation.
A final point that merits discussion is the rationale 
for the dose selection. While there is a slight increase in the 
response rate between 75 mg/m2 and 100 mg/m2 docetaxel 
in breast cancer patients, there is no significant difference 
in time to progression between the two doses [22]. Also, 
the higher toxicity of the 100 mg/m2 dose makes it difficult 
to administer in metastatic patients in combination with 
other investigational agents [23]. Many combination trials 
have used the 75 mg/m2 docetaxel dose as their preferred 
recommended phase II/III dose in patients with metastatic 
breast cancer for these reasons [24, 25]. A single 1200 
mg dose of indoximod almost totally saturates the gut, 
and higher doses do not significantly increase peak 
serum levels. This serves as our justification for moving 
forward with the recommended phase II dose of 75 mg/
m2 of docetaxel in combination with twice daily 1200 
mg of indoximod. A limitation of this data from a small 
phase 1 trial is that one cannot exclude the possibility that 
indoximod could exert better immunomodulatory effects 
at slightly higher or lower dose levels of docetaxel.
In summary, we found encouraging activity in 
a pre-treated population of patients with metastatic 
disease. According to the pharmacokinetic data, there 
were no drug-drug interactions between indoximod 
and docetaxel. The combination was well tolerated 
with a toxicity profile similar to docetaxel alone. The 
recommended phase II dose is 75 mg/m2 of docetaxel 
every 3 weeks in combination with 1200 mg indoximod 
PO twice daily. The response and safety data support the 
conclusion that this combination is feasible to administer 
and should be investigated further in a larger randomized 
phase II trial. A randomized, double blind, placebo-
controlled phase II study of docetaxel plus indoximod 
in metastatic breast cancer patients (NLG201) is now 
accruing patients.
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